| Selective translation of leaderless mRNAs by specialized ribosomes generated by MazF in Escherichia coli O Vesper, S Amitai, M Belitsky, K Byrgazov, AC Kaberdina, ... Cell 147 (1), 147-157, 2011 | 354 | 2011 |
| Ribosome heterogeneity: another level of complexity in bacterial translation regulation K Byrgazov, O Vesper, I Moll Current opinion in microbiology 16 (2), 133-139, 2013 | 130 | 2013 |
| Structural basis for the interaction of protein S1 with the Escherichia coli ribosome K Byrgazov, I Grishkovskaya, S Arenz, N Coudevylle, H Temmel, ... Nucleic Acids Research 43 (1), 661-673, 2015 | 66 | 2015 |
| Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia G Heller, T Topakian, C Altenberger, S Cerny-Reiterer, S Herndlhofer, ... Leukemia 30 (9), 1861-1868, 2016 | 62 | 2016 |
| The MazF-regulon: a toolbox for the post-transcriptional stress response in Escherichia coli M Sauert, MT Wolfinger, O Vesper, C Müller, K Byrgazov, I Moll Nucleic Acids Research 44 (14), 6660-6675, 2016 | 59 | 2016 |
| Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia KV Gleixner, M Schneeweiss, G Eisenwort, D Berger, H Herrmann, K Blatt, ... Haematologica 102 (9), 1519, 2017 | 44 | 2017 |
| Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1T315I-compound mutations KV Gleixner, Y Filik, D Berger, C Schewzik, G Stefanzl, I Sadovnik, ... American journal of cancer research 11 (9), 4470, 2021 | 41 | 2021 |
| Direct interaction of the N-terminal domain of ribosomal protein S1 with protein S2 in Escherichia coli K Byrgazov, S Manoharadas, AC Kaberdina, O Vesper, I Moll PLoS One 7 (3), e32702, 2012 | 38 | 2012 |
| BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib K Byrgazov, CB Lucini, P Valent, O Hantschel, T Lion Haematologica 103 (1), e10, 2018 | 30 | 2018 |
| Block synthesis of blood group tetrasaccharides B (types 1, 3 and 4) EY Korchagina, IM Ryzhov, KA Byrgazov, IS Popova, SN Pokrovsky, ... Mendeleev Communications 19 (3), 152-154, 2009 | 26 | 2009 |
| CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML M Schneeweiss-Gleixner, K Byrgazov, G Stefanzl, D Berger, G Eisenwort, ... EBioMedicine 50, 111-121, 2019 | 16 | 2019 |
| NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors K Byrgazov, R Kastner, M Gorna, G Hoermann, M Koenig, CB Lucini, ... Leukemia 31 (1), 237-240, 2017 | 12 | 2017 |
| Transposon-mediated generation of BCR-ABL1-expressing transgenic cell lines for unbiased sensitivity testing of tyrosine kinase inhibitors K Byrgazov, CB Lucini, B Berkowitsch, M Koenig, OA Haas, G Hoermann, ... Oncotarget 7 (47), 78083, 2016 | 11 | 2016 |
| Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide K Byrgazov, C Anderson, B Salzer, E Bozsaky, R Larsson, J Gullbo, ... Therapeutic Advances in Medical Oncology 12, 1758835920937891, 2020 | 10 | 2020 |
| Novel peptide-drug conjugate melflufen efficiently eradicates bortezomib-resistant multiple myeloma cells including tumor-initiating myeloma progenitor cells K Byrgazov, A Besse, M Kraus, A Slipicevic, F Lehmann, C Driessen, ... Hemasphere 5 (7), e602, 2021 | 9 | 2021 |
| Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs K Byrgazov, M Kraus, A Besse, A Slipicevic, F Lehmann, C Driessen, ... Leukemia research 101, 106499, 2021 | 8 | 2021 |
| A novel fusion gene NDEL1-Pdgfrb in a patient with JMML with a new variant of TKI-resistant mutation in the kinase domain of PDGFRβ K Byrgazov, R Kastner, M Dworzak, G Hoermann, OA Haas, R Ulreich, ... Blood 124 (21), 613, 2014 | 7 | 2014 |
| Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes K Byrgazov, T Lind, AJ Rasmusson, C Andersson, A Slipicevic, ... Bone Reports 15, 101098, 2021 | 5 | 2021 |
| A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1T315I in Ph+ CML KV Gleixner, I Sadovnik, M Schneeweiss, G Eisenwort, K Byrgazov, ... Leukemia research 78, 36-44, 2019 | 4 | 2019 |
| A peptidase-potentiated alkylating agent melflufen is effective anti-neoplastic agent in osteosarcoma K Byrgazov, A Slipicevic, F Lehmann, T Lion, L Kager, S Taschner-Mandl Annals of Oncology 30, v706, 2019 | 1 | 2019 |
